Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review

Boysen, Anders; Schou, Jesper Sølver; Spindler, Karen‐Lise Garm

doi:10.1007/s12094-018-1997-y

Cited by 11 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Together, these data suggest that total cfDNA at the time of diagnosis might have prognostic implications, while binary classifications based on the detection of ctDNA might not (in contrast to the situation at later time points, such as after chemoradiotherapy, curative surgery and/or completion of adjuvant therapy). In fact, a systematic review including data from nine studies and a total of 615 patients suggests a correlation between cfDNA level and clinical outcomes of response to neoadjuvant therapy, including DFS 58 . However, in another, larger systematic review of data from 25 studies, the investigators concluded that data are as yet inconclusive regarding the utility of pretreatment liquid biopsy or serial (pre-treatment and post-treatment) monitoring, but that the presence of MRD is consistently associated with worse outcomes across studies 59 .…”

Section: Box 3 | Key Recommendations On the Management Of Mrdmentioning

confidence: 99%

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

et al. 2020

View full text Add to dashboard Cite

An increasing number of studies are describing potential uses of circulating tumour DNA (ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area of research, the Colon and Rectal–Anal Task Forces of the United States National Cancer Institute convened a panel of multidisciplinary experts to summarize current data on the utility of ctDNA in the management of colorectal cancer and to provide guidance in promoting the efficient development and integration of this technology into clinical care. The panel focused on four key areas in which ctDNA has the potential to change clinical practice, including the detection of minimal residual disease, the management of patients with rectal cancer, monitoring responses to therapy, and tracking clonal dynamics in response to targeted therapies and other systemic treatments. The panel also provides general guidelines with relevance for ctDNA-related research efforts, irrespective of indication.

show abstract

Section: Box 3 | Key Recommendations On the Management Of Mrdmentioning

confidence: 99%

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Serial circulating tumor DNA (ctDNA) has shown to be a state-of-the-art biomarker for monitoring the survival benefits during the multimodality treatment of patients with LARC (3)(4)(5)(6)(7)(8). With advanced bioinformatic techniques such as next-generation sequencing (NGS) and whole genome sequencing (WGS) nowadays, processing data from circulating cell-free DNA (cfDNA) components could provide key genetic information of tumor phenotypes (9-11).…”

Section: Introductionmentioning

confidence: 99%

Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study

Zhou

Wang²,

Lin

et al. 2021

Clinical Cancer Research

104

View full text Add to dashboard Cite

are current employees of Geneplus-Beijing. C. Wang and Z. Yu are current employees of Geneplus-Shenzhen. L. Yang holds leadership positions of Geneplus-Beijing. The other authors declare no conflicts of interest. Translational Relevance Neoadjuvant chemoradiotherapy (nCRT) was the standard of care for patients with locally advanced rectal cancer (LARC), however the uniform regimen may not be applicable for all patients with different tumor loads and heterogeneous biological behaviors. In this study, the preoperative ctDNA status was significantly consistent with the postoperative pathological results, showing that ctDNA can accurately reflect the real-time tumor burden. Additionally, ctDNA showed a predictive ability for distant metastasis as early as prior to treatment. Besides, tumors with POLD1 mutation had significantly better response to nCRT than those without POLD1 mutation. These findings imply that ctDNA and tumor mutational information may potentially be powerful tools to guide the individualized multidisciplinary therapy for patients with LARC by assisting the selection of initial treatment strategies and regimens, or guiding the adjustment of treatment methods.

show abstract

“…A systematic review by Boyson et al. included nine single arm studies with a total of 615 patients undergoing chemoradiation for rectal cancer and investigated the relation between ctDNA and clinical outcomes ( 15 ). Eight of the nine studies showed some degree of correlation between ctDNA and either response to chemoradiation, risk of recurrence or disease-free survival.…”

Section: Discussionmentioning

confidence: 99%

“…In literature, several methods have been described to analyse the presence of ctDNA in peripheral blood samples, with different recommendations regarding pre-analytical conditions ( 12 – 14 ). In rectal cancer, two main ctDNA detection techniques are measuring the absolute number of cfDNA or identifying tumour-specific somatic mutations ( 15 ). These mutations are usually detected using polymerase chain reaction (PCR) or next-generation sequencing (NGS).…”

Section: Introductionmentioning

confidence: 99%

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

et al. 2023

View full text Add to dashboard Cite

BackgroundCirculating tumour DNA (ctDNA) has been established as a promising (prognostic) biomarker with the potential to personalise treatment in cancer patients. The objective of this systematic review is to provide an overview of the current literature and the future perspectives of ctDNA in non-metastatic rectal cancer.MethodsA comprehensive search for studies published prior to the 4th of October 2022 was conducted in Embase, Medline, Cochrane, Google scholar, and Web of Science. Only peer-reviewed original articles and ongoing clinical trials investigating the association between ctDNA and oncological outcomes in non-metastatic rectal cancer patients were included. Meta-analyses were performed to pool hazard ratios (HR) for recurrence-free survival (RFS).ResultsA total of 291 unique records were screened, of which 261 were original publications and 30 ongoing trials. Nineteen original publications were reviewed and discussed, of which seven provided sufficient data for meta-analyses on the association between the presence of post-treatment ctDNA and RFS. Results of the meta-analyses demonstrated that ctDNA analysis can be used to stratify patients into very high and low risk groups for recurrence, especially when detected after neoadjuvant treatment (HR for RFS: 9.3 [4.6 – 18.8]) and after surgery (HR for RFS: 15.5 [8.2 – 29.3]). Studies investigated different types of assays and used various techniques for the detection and quantification of ctDNA.ConclusionsThis literature overview and meta-analyses provide evidence for the strong association between ctDNA and recurrent disease. Future research should focus on the feasibility of ctDNA-guided treatment and follow-up strategies in rectal cancer. A blueprint for agreed-upon timing, preprocessing, and assay techniques is needed to empower adaptation of ctDNA into daily practice.

show abstract

Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review

Cited by 11 publications

References 28 publications

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

Contact Info

Product

Resources

About